Imatinib attenuates severe mouse dystrophy and inhibits proliferation and fibrosis-marker expression in muscle mesenchymal progenitors

Neuromuscular Disorders

Volumn 23, Issue 4, 2013, Pages 349-356

  Ito, Takahito ^a   Ogawa, Ryo ^a   Uezumi, Akiyoshi ^b   Ohtani, Takuji ^a   Watanabe, Yoko ^a   Tsujikawa, Kazutake ^a   Miyagoe Suzuki, Yuko ^c   Takeda, Shin'ichi ^c   Yamamoto, Hiroshi ^a   Fukada, So ichiro ^a  

^a OSAKA UNIVERSITY   (Japan)

^b FUJITA HEALTH UNIVERSITY   (Japan)

^c NATIONAL INSTITUTE OF NEUROSCIENCE   (Japan)

Author keywords

Imatinib; Muscular dystrophy; PDGFR ; Satellite cells

Indexed keywords

IMATINIB; PLATELET DERIVED GROWTH FACTOR AA; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL ISOLATION; CELL PROLIFERATION; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DISEASE SEVERITY; DRUG MECHANISM; DUCHENNE MUSCULAR DYSTROPHY; GASTROCNEMIUS MUSCLE; HISTOPATHOLOGY; IN VITRO STUDY; MESENCHYMAL STEM CELL; MONONUCLEAR CELL; MOUSE; MUSCLE INJURY; MYOBLAST; MYOFIBROSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUADRICEPS FEMORIS MUSCLE; REAL TIME POLYMERASE CHAIN REACTION; SATELLITE CELL; TIBIALIS ANTERIOR MUSCLE;

ANIMALS; BENZAMIDES; CELL PROLIFERATION; FIBROSIS; MESENCHYMAL STROMAL CELLS; MICE; MICE, INBRED DBA; MICE, INBRED MDX; MUSCLE FIBERS, SKELETAL; MUSCLE, SKELETAL; PIPERAZINES; PLATELET-DERIVED GROWTH FACTOR; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PYRIMIDINES; SATELLITE CELLS, SKELETAL MUSCLE; SIGNAL TRANSDUCTION;

EID: 84875000054     PISSN: 09608966     EISSN: 18732364     Source Type: Journal    
DOI: 10.1016/j.nmd.2012.10.025     Document Type: Article

References (21)

1. Collins C.A., Olsen I., Zammit P.S., et al. Stem cell function, self-renewal, and behavioral heterogeneity of cells from the adult muscle satellite cell niche. Cell 2005, 122:289-301.
2. Carpenter S., Karpati G. Disease of skeletal muscle. Pathology of skeletal muscle 2001, 373-524. Oxford University Press, Inc., New York, New York. 2nd ed.
3. Koenig M., Monaco A.P., Kunkel L.M. The complete sequence of dystrophin predicts a rod-shaped cytoskeletal protein. Cell 1988, 53:219-228.
4. Gargioli C., Coletta M., De Grandis F., Cannata S.M., Cossu G. PlGF-MMP-9-expressing cells restore microcirculation and efficacy of cell therapy in aged dystrophic muscle. Nat Med 2008, 14:973-978.
5. Uezumi A., Ito T., Morikawa D., et al. Fibrosis and adipogenesis originate from a common mesenchymal progenitor in skeletal muscle. J Cell Sci 2011, 124:3654-3664.
6. Uezumi A., Fukada S., Yamamoto N., Takeda S., Tsuchida K. Mesenchymal progenitors distinct from satellite cells contribute to ectopic fat cell formation in skeletal muscle. Nat Cell Biol 2010, 12:143-152.
7. Olson L.E., Soriano P. Increased PDGFRalpha activation disrupts connective tissue development and drives systemic fibrosis. Dev Cell 2009, 16:303-313.
8. Huang P., Zhao X.S., Fields M., Ransohoff R.M., Zhou L. Imatinib attenuates skeletal muscle dystrophy in mdx mice. FASEB J 2009, 23:2539-2548.
9. Bizario J.C., Cerri D.G., Rodrigues L.C., et al. Imatinib mesylate ameliorates the dystrophic phenotype in exercised mdx mice. J Neuroimmunol 2009, 212:93-101.
10. Fukada S., Morikawa D., Yamamoto Y., et al. Genetic background affects properties of satellite cells and mdx phenotypes. Am J Pathol 2010, 176:2414-2424.
11. Uezumi A., Ojima K., Fukada S., et al. Functional heterogeneity of side population cells in skeletal muscle. Biochem Biophys Res Commun 2006, 341:864-873.
12. Fukada S., Uezumi A., Ikemoto M., et al. Molecular signature of quiescent satellite cells in adult skeletal muscle. Stem Cells 2007, 25:2448-2459.
13. Fukada S., Higuchi S., Segawa M., et al. Purification and cell-surface marker characterization of quiescent satellite cells from murine skeletal muscle by a novel monoclonal antibody. Exp Cell Res 2004, 296:245-255.
14. Antoniades H.N., Scher C.D., Stiles C.D. Purification of human platelet-derived growth factor. Proc Natl Acad Sci USA 1979, 76:1809-1813.
15. Joe A.W., Yi L., Natarajan A., et al. Muscle injury activates resident fibro/adipogenic progenitors that facilitate myogenesis. Nat Cell Biol 2010, 12:153-163.
16. Zhao Y., Haginoya K., Sun G., Dai H., Onuma A., Iinuma K. Platelet-derived growth factor and its receptors are related to the progression of human muscular dystrophy: an immunohistochemical study. J Pathol 2003, 201:149-159.
17. Jones R.L., Judson I.R. The development and application of imatinib. Expert Opin Drug Saf 2005, 4:183-191.
18. Daniels C.E., Wilkes M.C., Edens M., et al. Imatinib mesylate inhibits the profibrogenic activity of TGF-beta and prevents bleomycin-mediated lung fibrosis. J Clin Invest 2004, 114:1308-1316.
19. Wang S., Wilkes M.C., Leof E.B., Hirschberg R. Imatinib mesylate blocks a non-Smad TGF-beta pathway and reduces renal fibrogenesis in vivo. Faseb J 2005, 19:1-11.
20. Cwynarski K., Laylor R., Macchiarulo E., et al. Imatinib inhibits the activation and proliferation of normal T lymphocytes in vitro. Leukemia 2004, 18:1332-1339.
21. Kerkela R., Grazette L., Yacobi R., et al. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med 2006, 12:908-916.